Search results for "Anticoagulation"

Results 1 - 19 of about 19 for "Anticoagulation".

Apixaban appears safer than rivaroxaban, warfarin in cirrhosis with atrial fibrillation

Patients who initiated rivaroxaban or warfarin had significantly higher rates of major hemorrhagic events than those taking apixaban, a retrospective study of U.S. patients with cirrhosis and nonvalvular atrial fibrillation found.
https://immattersacp.org/weekly/archives/2024/07/09/1.htm
9 Jul 2024

Home-based INR monitoring associated with fewer adverse events

An industry-funded, claims-based analysis found that patients on warfarin who tested their international normalized ratio (INR) at home had lower rates of stroke, thromboembolism, and major bleeding than patients whose INRs were measured at physicians' offices or in laboratories.
https://immattersacp.org/weekly/archives/2024/01/02/4.htm
2 Jan 2024

Use of warfarin down, DOACs up in commercially insured patients with cirrhosis, nonvalvular afib

While more than half of eligible patients with cirrhosis and concurrent nonvalvular atrial fibrillation did not receive anticoagulation between 2012 and 2019, use of direct oral anticoagulants (DOACs) increased substantially during that time, a recent study found.
https://immattersacp.org/weekly/archives/2023/01/17/4.htm
17 Jan 2023

Managing DOACs in primary care

Primary care physicians play a crucial role in ongoing anticoagulation management, including educating patients about the signs of venous thromboembolism.
https://immattersacp.org/archives/2022/04/managing-doacs-in-primary-care.htm
1 Apr 2022

Dabigatran may interact with BP meds in patients with afib and normal kidney function

U.S. guidance currently recommends a lower dabigatran dose in those taking P-glycoprotein inhibitors only if kidney function is impaired.
https://immattersacp.org/weekly/archives/2020/04/28/4.htm
28 Apr 2020

Pros, cons of prolonged anticoagulation after a clot

Experts debate about provoked vs. unprovoked venous thromboembolism, and whether a once-high-risk patient can have that status removed later.
https://immattersacp.org/archives/2020/02/pros-cons-of-prolonged-anticoagulation-after-a-clot.htm
1 Feb 2020

Non-vitamin K oral anticoagulants appear superior to vitamin K antagonists in early-stage CKD

An accompanying editorial said that the current review supports a superior benefit profile of non-vitamin K oral anticoagulants (NOACs) in patients with atrial fibrillation and early-stage chronic kidney disease (CKD).
https://immattersacp.org/weekly/archives/2019/07/16/2.htm
16 Jul 2019

Nuisance bleeding on oral anticoagulation not associated with risk of major bleeding

Nuisance bleeding should not lead to changes in anticoagulation strategies in patients treated with oral anticoagulation, researchers concluded.
https://immattersacp.org/weekly/archives/2018/05/01/1.htm
1 May 2018

Tailoring anticoagulation more of a reality with DOACs

Direct oral anticoagulants have the potential to replace warfarin for the treatment of many patients with venous thromboembolism, but without a need for routine monitoring, good patient selection is key to their use.
https://immattersacp.org/archives/2018/03/tailoring-anticoagulation-more-of-a-reality-with-doacs.htm
1 Mar 2018

Early oral anticoagulation in afib may protect against dementia

Taking anticoagulant treatment at baseline was associated with a 29% lower risk of dementia than not receiving anticoagulant treatment and a 48% lower risk when analyzed on treatment.
https://immattersacp.org/weekly/archives/2017/10/31/1.htm
31 Oct 2017

Early hormone therapy in menopause doesn't seem to affect atherosclerosis progression

Hormone therapy begun early in menopause improved some markers of cardiovascular disease (CVD) risk but did not appear to affect atherosclerosis progression, a study found.
https://immattersacp.org/weekly/archives/2014/07/29/5.htm
29 Jul 2014

BMJ investigation claims safety info about dabigatran withheld by manufacturer

The makers of dabigatran allegedly failed to share information with regulators that would make using the drug safer—specifically, that monitoring plasma levels of the drug and adjusting doses accordingly could significantly reduce major bleeding, a new BMJ investigation found.
https://immattersacp.org/weekly/archives/2014/07/29/4.htm
29 Jul 2014

Warfarin given to elderly patients within a year of traumatic brain injury associated with net benefit

Resuming warfarin in the year after a traumatic brain injury was associated with a net benefit, due to a reduction in ischemic stroke risk, for elderly patients in a recent study.
https://immattersacp.org/weekly/archives/2014/06/17/5.htm
17 Jun 2014

Rivaroxaban has similar safety, efficacy versus warfarin in older and younger nonvalvular afib patients

Rivaroxaban appears to have similar safety and efficacy compared with warfarin in both older and younger patients with nonvalvular atrial fibrillation, although stroke and major bleeding rates were higher in the former group, a new study found.
https://immattersacp.org/weekly/archives/2014/06/10/6.htm
10 Jun 2014

Oral anticoagulants and antiplatelets compared for risk of recurrent VTE, major bleeds

All oral anticoagulants and antiplatelet agents reduced recurrence of venous thromboembolism (VTE) compared with placebo, with aspirin reducing risk the least and vitamin K antagonists reducing it the most, a meta-analysis found.
https://immattersacp.org/weekly/archives/2013/09/10/5.htm
10 Sep 2013

Dabigatran noninferior to warfarin for preventing VTE recurrence

In patients who had a previous venous thromboembolism (VTE), dabigatran prevented recurrence about as well as warfarin and caused fewer bleeding events, according to two new manufacturer-sponsored trials of extended treatment.
https://immattersacp.org/weekly/archives/2013/02/26/5.htm
26 Feb 2013